According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast ...

Halo Pharma's transition to a standalone CDMO allows a concentrated focus on drug product services, enhancing technical ...

Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal ...

Union Budget 2026 | Investor attention is expected to turn to active pharmaceutical ingredient (API) makers, specialty drug ...

Market valued at $72.4M in 2024, projected 7.30% CAGR growth driven by pharmaceutical API synthesis, food-grade ...

In the evolving landscape of pharmaceutical development, modified release (MR) tablets have emerged as a cornerstone technology for improving therapeutic outcomes and patient compliance. Unlike ...

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

The company is eyeing a revenue of Rs 1,000 crore by 2028 and expects its API plant in Navi Mumbai, which was damaged in a fire in 2025, to resume complete operations by March, Nair tells Moneycontrol ...

India’s largest drug-maker Sun Pharmaceutical Industries posted a 16 per cent year-on-year (Y-o-Y) growth in its consolidated profit after tax (PAT) at Rs 3,369 crore for the third quarter of the ...

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present new safety and ...

Halo Pharma, a CDMO, will become a stand-alone business as a result of the sale of the Noramco API and associated businesses ...

The Fine and Specialty Chemicals Market is entering a transformative phase of high-value innovation and application-specific ...